Otlertuzumab - CAS 1372645-37-8

Otlertuzumab (TRU-016) is a humanized monoclonal antibody that specifically targets the CD37 antigen, which is highly expressed on the surface of B-cells. this targeted mechanism of action supports its ongoing clinical investigation for the treatment of relapsed or refractory B-cell malignancies, including follicular non-Hodgkin lymphoma (FL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinaemia (WM) .

Others

Others

1372600

0.996

-20°C

Ice Packs

Inhibitory Antibodies